Cavco Industries, Inc. (CVCO) EPS Estimated At $0.00; 3 Analysts Bullish Ocera Therapeutics (OCRX)

Analysts expect Cavco Industries, Inc. (NASDAQ:CVCO) to report $0.00 EPS on May, 25. About 7,471 shares traded. Cavco Industries, Inc. (NASDAQ:CVCO) has risen 20.51% since September 28, 2016 and is uptrending. It has outperformed by 10.46% the S&P500.

Among 4 analysts covering Ocera Therapeutics (NASDAQ:OCRX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Ocera Therapeutics had 5 analyst reports since November 6, 2015 according to SRatingsIntel. The rating was initiated by Aegis Capital on Friday, November 4 with “Buy”. The company was initiated on Tuesday, February 23 by Brean Capital. JMP Securities downgraded the stock to “Mkt Perform” rating in Tuesday, January 31 report. The stock has “Buy” rating by H.C. Wainwright on Wednesday, December 28. See Ocera Therapeutics Inc (NASDAQ:OCRX) latest ratings:

31/01/2017 Broker: JMP Securities Old Rating: Mkt Outperform New Rating: Mkt Perform Downgrade
28/12/2016 Broker: H.C. Wainwright Rating: Buy New Target: $10 Initiate

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $31.42 million. The Firm is focused on acute and chronic orphan liver diseases. It currently has negative earnings. The Firm is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy .

Since December 7, 2016, it had 2 insider purchases, and 0 selling transactions for $18,834 activity. Byrnes Michael also bought $3,854 worth of Ocera Therapeutics Inc (NASDAQ:OCRX) shares. Grais Linda S bought 7,000 shares worth $14,980.

About 60,991 shares traded. Ocera Therapeutics Inc (NASDAQ:OCRX) has declined 55.47% since September 28, 2016 and is downtrending. It has underperformed by 65.52% the S&P500.

Investors sentiment increased to 2.57 in 2016 Q4. Its up 1.35, from 1.22 in 2016Q3. It increased, as 2 investors sold Ocera Therapeutics Inc shares while 5 reduced holdings. 6 funds opened positions while 12 raised stakes. 6.54 million shares or 4.63% less from 6.86 million shares in 2016Q3 were reported. Great Point Prns Limited Liability reported 0.85% stake. New York-based Pura Vida Invests Ltd Llc has invested 0.2% in Ocera Therapeutics Inc (NASDAQ:OCRX). Northern Trust reported 13,318 shares. New York-based Fincl Bank Of New York Mellon Corp has invested 0% in Ocera Therapeutics Inc (NASDAQ:OCRX). Vhcp Limited holds 2.06% or 912,050 shares. 906,286 were accumulated by Qvt Financial Limited Partnership. Ipg Invest Ltd Co reported 13,000 shares. Stifel Financial Corporation has 0% invested in Ocera Therapeutics Inc (NASDAQ:OCRX). Blackrock Ltd Liability Corporation accumulated 2,764 shares or 0% of the stock. Deerfield Com holds 0.05% of its portfolio in Ocera Therapeutics Inc (NASDAQ:OCRX) for 572,893 shares. Manufacturers Life Insurance The holds 0% or 1,755 shares in its portfolio. Susquehanna Group Llp owns 34,751 shares. Geode Mngmt Lc has 0% invested in Ocera Therapeutics Inc (NASDAQ:OCRX) for 61,088 shares. Creative Planning holds 0% in Ocera Therapeutics Inc (NASDAQ:OCRX) or 1,500 shares. Glenmede Tru Company Na reported 28,200 shares stake.

Cavco Industries, Inc. designs and produces factory-built homes. The company has market cap of $1.05 billion. The Firm operates through two divisions: factory-built housing, which includes wholesale and retail systems-built housing operations, and financial services, which includes manufactured housing consumer finance and insurance. It has a 31.15 P/E ratio. The Company’s factory-built homes are primarily distributed through a network of independent and the Company-owned retailers, planned community operators and residential developers.